Clusterin (apolipoprotein J): Wither link with diabetes and cardiometabolic risk?

Metabolism: Clinical and Experimental

Volumn 60, Issue 6, 2011, Pages 747-748

  Aronis, Konstantinos N ^a   Kim, Young Bum ^a   Mantzoros, Christos S ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; CLUSTERIN; COMPLEMENT COMPONENT C3D; COMPLEMENT MEMBRANE ATTACK COMPLEX; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; EDITORIAL; HUMAN; METABOLIC SYNDROME X; NEOPLASM; PRIORITY JOURNAL;

CARDIOVASCULAR DISEASES; CLUSTERIN; DIABETES MELLITUS; HUMANS; INFLAMMATION; LIPID METABOLISM; METABOLIC SYNDROME X; NEOPLASMS; POLYMORPHISM, GENETIC; RISK;

EID: 79956069883     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2010.12.013     Document Type: Editorial

References (21)

1. Fritz IB, Burdzy K, Sétchell B, et al. Ram rete testis fluid contains a protein (clusterin) which influences cell-cell interactions in vitro. Biol Reprod 1983;28:1173-88. (Pubitemid 13037974)
2. Blaschuk O, Burdzy K, Fritz IB. Purification and characterization of a cell-aggregating factor (clusterin), the major glycoprotein in ram rete testis fluid. J Biol Chem 1983;258:7714-20. (Pubitemid 13038010)
3. de Silva HV, Stuart WD, Park YB, et al. Purification and characterization of apolipoprotein J. J Biol Chem 1990;265:14292-7.
4. de Silva HV, Stuart WD, Duvic CR, et al. A 70-kDa apolipoprotein designated ApoJ is a marker for subclasses of human plasma high density lipoproteins. J Biol Chem 1990;265:13240-7.
5. Bettuzzi S. Conclusions and perspectives. Adv Cancer Res 2009;105:133-50 Review.
6. Van Dijk A, Vermond RA, Krijnen PA, et al. Intravenous clusterin administration reduces myocardial infarct size in rats. Eur J Clin Invest 2010;40:893-902.
7. ter Weeme M, Vonk AB, Kupreishvili K, et al. Activated complement is more extensively present in diseased aortic valves than naturally occurring complement inhibitors: a sign of ongoing inflammation. Eur J Clin Invest 2010;40:4-10 [Epub 2009 Oct 15].
8. Rizzi F, Bettuzzi S. Clusterin (CLU) and prostate cancer. Adv Cancer Res 2009;105:1-19 [Review].
9. Miyake H, Muramaki M, Furukawa J, et al. Serum level of clusterin and its density in men with prostate cancer as novel biomarkers reflecting disease extension. Urology 2010;75:454-9 [Epub 2009 Oct 24].
10. Bi J, Guo AL, Lai YR, et al. Overexpression of clusterin correlates with tumor progression, metastasis in gastric cancer: a study on tissue microarrays. Neoplasma 2010;57:191-7.
11. Flanagan L, Whyte L, Chatterjee N, et al. Effects of clusterin over-expression on metastatic progression and therapy in breast cancer. BMC Cancer 2010;10:107.
12. Dia VP, Mejia EG. Lunasin promotes apoptosis in human colon cancer cells by mitochondrial pathway activation and induction of nuclear clusterin expression. Cancer Lett 2010;295:44-53 [Epub 2010 Mar 4].
13. Pucci S, Bonanno E, Sesti F, et al. Clusterin in stool: a new biomarker for colon cancer screening? Am J Gastroenterol 2009;104:2807-15 [Epub 2009 Jul 21].
14. Watari H, Kanuma T, Ohta Y, et al. Clusterin expression inversely correlates with chemosensitivity and predicts poor survival in patients with locally advanced cervical cancer treated with cisplatin-based neoadjuvant chemotherapy and radical hysterectomy. Pathol Oncol Res 2010;16:345-52 [Epub 2010 Jan 8].
15. Watari H, Ohta Y, Hassan MK, et al. Clusterin expression predicts survival of invasive cervical cancer patients treated with radical hysterectomy and systematic lymphadenectomy. Gynecol Oncol 2008;108:527-32 [Epub 2008 Jan 4].
16. Yang GF, Li XM, Xie D. Overexpression of clusterin in ovarian cancer is correlated with impaired survival. Int J Gynecol Cancer 2009;19:1342-6.
17. Kujiraoka T, Hattori H, Miwa Y, et al. Serum apolipoprotein j in health, coronary heart disease and type 2 diabetes mellitus. J Atheroscler Thromb 2006;13:314-22.
18. Trougakos IP, Poulakou M, Stathatos M, et al. Serum levels of the senescence biomarker clusterin/apolipoprotein J increase significantly in diabetes type II and during development of coronary heart disease or at myocardial infarction. Exp Gerontol 2002;37:1175-87.
19. Hoofnagle AN, Wu M, Gosmanova AK, et al. Low clusterin levels in high-density lipoprotein associate with insulin resistance, obesity, and dyslipoproteinemia. Arterioscler Thromb Vasc Biol 2010;30:2528-34 [Epub 2010 Sep 16].
20. Daimon M, Oizumi T, Karasawa S, et al. Association of the clusterin gene polymorphisms with type 2 diabetes mellitus. Metabolism (in press).
21. Bajari TM, Strasser V, Nimpf J, Schneider WJ. A model for modulation of leptin activity by association with clusterin. FASEB J 2003;17:1505-7.